NEW YORK--(BUSINESS WIRE)--Jan. 12, 2006--Medis Technologies Ltd. (NASDAQ:MDTL) announced today that its scientists have achieved a breakthrough in the use of the CellScan System, allowing much longer survival of cells and the opportunity for their measurement. This breakthrough paves the way to important contributions in various areas of cancer research, including in the cutting edge research area of cancer stem cells, as well as providing a significant new tool in drug development. Medis has developed a new proprietary version of the CellScan Cell Carriers which hold up to ten thousand individual cells, particularly in providing various new coatings of the Cell Carriers. The new Cell Carrier allows the cells to survive and be measured for over 48 hours, which provides an opportunity for measuring the reaction of different cells and separating out those cells whose reaction warrants further stimulation or study, including testing the efficacy of drugs on those cells. To Medis’ knowledge, this ability to repeatedly measure the reaction of individual living cells by their fluorescence intensity and polarization over such an extended period of time has not been available to the scientific and medical communities until now with the CellScan. Medis is in the process of filing patent applications for this new Cell Carrier development.